5 Supercharged Pharma Stocks Set to Skyrocket in 2023! Don’t Miss Out!

Stocks

Stock	Price	52 Week Range	Marketcap	EPS	Dividend Yield	Chart (24H)	Sector	Employees	Last Updated
Johnson & Johnson JNJ	$178.84		430.71B	9.34	2.91%		Healthcare	138,100	12 hours ago
Bristol-Myers Squibb Company BMY	$48.26		98.23B	2.49	5.14%		Healthcare	34,100	12 hours ago
979656 WPI	$0.0000		0.0000	0.00	0.00%			0	6 years ago
Royalty Pharma plc RPRX	$36.88		21.51B	2.29	2.39%		Healthcare	0	12 hours ago

In today’s dynamic market, savvy investors are always on the lookout for potential high-profit stocks. The pharmaceutical sector stands out as a fertile ground for such opportunities. Our focus on five standout pharmaceutical stocks, recently upgraded by the trusted Portfolio Grader tool, reveals why these stocks are worthy of attention. The Portfolio Grader, a proprietary stock ranking system by Louis Navellier, assesses around 5,000 companies weekly using fundamental and quantitative measures, making its ratings highly reliable.

Let’s dive deeper into these pharmaceutical gems that have shown notable improvements and are positioning themselves as strong buys.

Editor's Note: Analysis and insight for this article were originally sourced from our friends at InvestorPlace 

Alimera Sciences (NASDAQ: ALIM)

Why It’s a Good Investment:

Alimera Sciences, a standout in the ophthalmic pharmaceuticals niche, has recently caught the market’s eye. The company’s specialization in treating eye diseases provides it with a competitive edge in a less crowded market. This specialization has contributed significantly to its impressive rating jump from a “C” (hold) to a “B” (buy) on Navellier’s Portfolio Grader.

Over the past month, Alimera Sciences’ stock price has surged by an astounding 46.4%, starkly outperforming Nasdaq’s modest 5.1% increase. The considerable price rise reflects a robust market momentum, backed by investor confidence and positive business developments. This is a strong indicator that Alimera’s market position is strengthening, suggesting that the company is on a trajectory for continued success. The firm engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals, targeting a high-demand, specialized area poised for growth.

Analyst Ratings Overview:

Here is the analyst ratings and forecasts table for Alimera Sciences (ALIM):